中国生物制药(01177.HK)旗下抗肿瘤药「甲磺酸伊马替尼胶囊」获一致性评价
中国生物制药(01177.HK)公布,附属公司正大天晴药业集团股份有限公司的抗肿瘤药「甲磺酸伊马替尼胶囊」(商品名称「格尼可」)获得国家药品监督管理局批准通过仿制药质量和疗效一致性评价。
甲磺酸伊马替尼是一种Bcr-Abl酪氨酸激(酉每)抑制剂,用於治疗慢性髓性白血病(CML)的急变期、加速期或干扰素治疗失败的慢性期患者。
公司指,通过了一致性评价,格尼可获确认其品质和疗效与原研药一致,可实现原研药的临床替代,能为患者提供优质低价的用药选择,同时也使该产品在市场拓展、医保支付等层面上可获得更多优势。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.